FNDC5 and prostate carcinoma: Treating metastatic PC3 prostate cancer cells with variable irisin concentrations (5 to 100 nmol/L) for 24, 48, and 72 h in another study also promoted cell death and upregulated several markers of apoptosis in vitro and in a xenograft animal model [44].